# Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

> **NCT00141726** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Lung Injury, Acute
- Respiratory Distress Syndrome, Adult
- Bronchiolitis Obliterans

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00141726
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2008-07
- **Final completion:** 2009-02
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141726, "Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00141726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*